Clinical trial Recruiting at 1 site Interventional Ages 16 to 40

Bone stimulator treatment for spondylolysis in athletes

Official title: The Efficacy of Bone Stimulator in Treatment and Return-to-Sport for Spondylolysis

Run by The Methodist Hospital Research Institute · NCT06666608 · Data updated 2026-11-12

This project will test whether adding a bone stimulator to usual care helps athletes aged 16 to 40 with symptomatic spondylolysis reduce pain, improve function, heal the bone, and return to sport sooner.

Quick facts

Study typeInterventional
Ages16 Years to 40 Years
SexAll
Enrollment48 (estimated)
SponsorThe Methodist Hospital Research Institute
Academic / other
Locations1 site (Houston, Texas)
StatusRecruiting
StartedDecember 3, 2025
Main results expectedDecember 2027
Study endsDecember 2029
Registry record updatedMarch 25, 2026
Trial IDNCT06666608 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are athletes aged 16 to 40 with symptomatic spondylolysis who can attend prescribed physical therapy and have no contraindications to bone stimulation.

Probably not a fit

Patients with prior spine surgery, implanted cardiac devices, metabolic bone disease, nicotine use, or other contraindications are unlikely to be eligible or to benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective interventional study enrolling athletes with symptomatic spondylolysis who will receive bone stimulation in addition to standard-of-care treatment and prescribed physical therapy, compared with those receiving standard care alone. Investigators will track outcomes including pain scores, functional improvement, radiographic osseous union, and time to return to sport. Key eligibility includes ages 16–40, regular sports participation, and ability to attend physical therapy, while exclusions include prior spine surgery, pacemaker/ICD, metabolic bone disease, nicotine use, and other contraindications. The study is conducted at Houston Methodist Hospital and targets athletic populations to define the adjunct role of bone stimulation for pars defects.

Why it matters

Potential benefit: If successful, adding bone stimulation could speed bone healing, reduce pain, and shorten time to return to sport for athletes with spondylolysis.

How similar studies have gone: Bone stimulators have demonstrated benefit for certain fractures and nonunions, but data specifically for spondylolysis in athletes are limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients between the ages of 16 to 40 years of age diagnosed with symptomatic spondylolysis by one of the investigators
* Patients who plan to attend prescribed physical therapy
* Patients who participate in a regular sport whether that be professional, collegiate or recreational

Exclusion Criteria:

* Any condition which in the investigator's opinion, would interfere with the subject's ability to comply with study instructions
* Patients with contraindications to bone stimulator therapy
* Patients with pacemaker and implantable cardioverter defibrillator
* Patients with previous spine surgery
* Patients with metabolic bone conditions
* Patients who use nicotine products
* Vulnerable populations
* Non-English speaking services

Where it's running

  • Houston Methodist Hospital
    Houston, Texas, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.